Identifai Genetics Limited (ASX: ID1)
Health Care · Biotechnology · AU
AU$0.38
-2.56% today · +52.0% 1Y
Identifai Genetics Limited (ASX: ID1) operates in the Biotechnology industry within the Health Care sector. The company is valued at $49.25M.
Over the last twelve months the share price has gained 52.0%, trading between 0.22 and 0.56.
Tweenvest scores Identifai Genetics Limited across four factors: quality 57/100. Its strongest factor is quality.
ID1 price history
Key figures
- Market cap
- $49.25M
- Revenue (TTM)
- —
- P/E
- -46.56
- EPS
- -2.11
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- AU$0.56
- 52-week low
- AU$0.22
- Avg volume (3M)
- —
- Shares outstanding
- 191.98M
- Employees
- —
- Next earnings
- —
About Identifai Genetics Limited
Identifai Genetics Limited provides prenatal genetic screening through the application of genome-wide sequencing and artificial intelligence in Israel, the United States, Hong Kong, China, and Australia. The company's product, Windrose, is a first-trimester non-invasive prenatal test that provides cfDNA-based fetal risk assessment for more than 280 clinically actionable genes, all from a single blood draw and without requiring a partner sample. The company was founded in 2021 and is based in Subiaco, Australia.
- ISIN
- AU0000488983
- Founded
- 2021
- Listed since
- Oct 8, 2026
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Biomolecular Life Holdings, Inc.OTCPK: BIOM | $50.65M | $0.99 | +43.48% |
| Heron Therapeutics, Inc.NasdaqCM: HRTX | $50.25M | $0.26 | -3.26% |
| RenovoRx, Inc.NasdaqCM: RNXT | $50.18M | $1.04 | -10.34% |
| Gain Therapeutics, Inc.NasdaqGM: GANX | $49.42M | $1.11 | -5.93% |
| Clene Inc.NasdaqCM: CLNN | $49.25M | $3.42 | +6.21% |
| Quantum Cyber N.V.NasdaqCM: QUCY | $49.10M | $0.58 | -6.31% |
| Optipharm.CO.,LTDKOSDAQ: A153710 | $49.05M | ₩4,470.00 | +1.94% |
| Zelluna ASAOB: ZLNA | $48.88M | Nkr15.65 | -2.80% |